We thank a lot the ECIL group for updating the antifungal guidelines for fungal management in leukemia patients and those undergoing SCT and for providing useful data to treat them in the best way.
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Based on preliminary results of a randomized study comparing voriconazole with fluconazole the latter is positioned as provisional AI score for prophylaxis after allogeneic transplantation. 2 This paper has been published in extenso, and the fungal free survival at 180 days (primary end point of the study) was similar in patients prophylaxed with voriconazole or fluconazole (78 vs 75%).
However, the risk of invasive fungal infection (IFI) is not the same for all allografted patients. In Wingard's study, voriconazole was protective in high-risk acute leukemia patients, reducing the incidence of IFI and improving the fungal free survival, suggesting that in these patients with a clinical history of a aplastic long period, prophylaxis with active anti mold drugs is useful. Moreover, the incidence of IFI is not the same for all patients on the basis of different kind of transplantation, as recently suggested by the TRANSNET study, in which the IFI incidence is higher when the donor is not an HLA identical sibling. 3 Thus, even if an ad hoc study on highest risk subgroups is missing, we think that prophylaxis with mold active agents should not be adopted for all allografted patients, avoiding an overuse of voriconazole in patients at low risk to developed mold infections. According to this hypothesis, the GITMO group recently published a consensus conference on prophylaxis and treatment of IFI in this kind of patient, suggesting a risk-adapted approach to preventing IFI.
